Stem cell therapies, regenerative medicine, tissue engineering, and cellular reprogramming
338 articles
Scientists identify FGF10 as a key factor that reverses senescence in nucleus pulposus stem cells, pointing to a targeted therapy for chronic low back pain.
A clinical guide to what is injected under the stem cell label, why the cells mostly act through what they secrete rather than by becoming new tissue, where the approved therapies and controlled trials actually sit, and how to judge a clinic's claims.
Scientists uncover how RNA splicing and histone modification interact to supercharge chemical reprogramming, opening new doors for regenerative medicine.
How hyperbaric oxygen works, which indications rest on real evidence, what the telomere and cognition trials did and did not show, and how to counsel a patient weighing a 60-session course or a home soft chamber.
Fibroblasts from spiny mice prefer glycolysis over mitochondrial respiration, producing less ROS and staying resilient to oxidative stress across their entire lifespan.
Extracellular vesicles drive age-related immune decline and myeloid skewing — but young-cell EVs may restore aging blood stem cell function.
Scientists are building 'immunoids' — organoids from human stem cells that include functional immune components — to model disease and test therapies.
Young B-cell-derived LTβ reprograms aged periportal hepatocytes, restoring liver regeneration — with an agonist antibody replicating the effect.
New research reveals how peak nighttime melatonin triggers mitochondrial cleanup and metabolic shifts that boost blood stem cell regenerative power.
Satellite cells, the stem cells that repair muscle, lose function with age. New single-cell insights reveal why — and how to reverse it.
A mechanistic look at which bloodstream factors have causal support in aging, how experimental designs separate them, and why plasma dilution complicates the young-factor story.
Which molecules and cells in blood actually drive tissue aging? A closer look at B2M, VCAM1, TIMP2, exercise-induced factors, and the case for diluting old plasma instead of adding young.
